The safety of Esmya is being reviewed by the European Medicines Agency (EMA) following a new case of hepatic failure needing liver transplantation.
The latest case occurred despite safety measures introduced after a 2018 EMA review which concluded that there is a risk of rare but serious liver injury with ulipristal acetate for the treatment of uterine fibroids.
The MHRA has advised healthcare professionals to contact patients currently taking Esmya as soon as possible, stop their treatment and discuss other treatment options as appropriate. Clinicians must not start any new patients on Esmya.
Patients who have recently been prescribed the drug should be asked to seek immediate medical attention if they develop signs and symptoms of liver injury, including nausea, vomiting, malaise, right hypochondrial pain, anorexia, asthenia or jaundice. Liver function tests must be performed two to four weeks after stopping treatment.
Healthcare professionals have also been asked to report any suspected adverse drug reactions without delay to the Yellow Card Scheme.
There are currently no concerns with the use of the emergency contraceptive, ellaOne, which also contains ulipristal acetate (single dose, 30mg).